Interferon-α-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy

Cancer

Volumn 83, Issue 9, 1998, Pages 1938-1946

  Shah, Manisha ^a   Jenis, Edwin H ^b   Mookerjee, Basab K ^c   Schriber, Jeffrey R ^a   Baer, Maria R ^a   Herzig, Geoffrey P ^a   Wetzler, Meir ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Millard Fillmore Gates Hospital   (United States)

^c Western New York Healthcare System   (United States)

Author keywords

Chronic myeloid leukemia; Interferon ; Proteinuria; Renal failure

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 2; ITRACONAZOLE; MERCAPTOPURINE; METHYLPREDNISOLONE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PROTEINURIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IDARUBICIN; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MALE; PROTEINURIA;

EID: 0032211367     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981101)83:9<1938::AID-CNCR9>3.0.CO;2-M     Document Type: Article

References (53)

1. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman LU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-43.
2. Sacchi S, Kantarajan H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995;13:2401-7.
3. Ronnblom LE, Aim GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
4. Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, van Ypersele de Strihou C. Renal thrombotic microangiopathy in patients with chronic myelogenous leukemia treated with interferon-α2b. Nephrol Dial Transplant 1995;10:111-3.
5. Schlaifer D, Dumazer P, Spenatto N, Mignon-Conte M, Brousset P, Lumbroso C, et al. Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha [letter]. Am J Hematol 1994;47:254-5.
6. Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon alpha. Am J Kidney Dis 1992;20:516-8.
7. Rettmar K, Kienast J, Van de Loo J. Minimal change glomerulonephritis with reversible proteinuria during interferon α2a therapy for chronic myeloid leukemia [letter]. Am J Hematol 1995;49:355-6.
8. Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. Br Med J 1985;290:1180.
9. Fahal IH, Murry N, Chu P, Bell GM. Acute renal failure during interferon treatment. Br Med J 1993;306:973.
10. Sawamura M, Matsushima T, Tamura J, Murakama H, Tsuchiya J. Renal toxicity in long-term α-interferon treatment in a patient with myeloma [letter]. Am J Hematol 1992;41:146.
11. Noel C, Vrtovsnik F, Facon T, Noel-Walter MP, Hazzan M, Jouet JP, et al. Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: report of two patients [letter]. Am J Hematol 1992;41:298-9.
12. Cooper MR, Fefer A, Thompson J, Case DC Jr., Kempf R, Sacher R, et al. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a Phase I-II trial. Cancer Treat Rep 1986;70:473-6.
13. Averbuch SD, Austin HA III, Sherwin SA, Antonovych T, Bunn PA Jr., Longo DL. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 1984;310:32-5.
14. Nair S, Ernstoff MS, Bahson RR, Arthur S, Johnston J, Downs MA, et al. Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology 1992;29:169-72.
15. Horowitz R, Glocklich D, Sablay LB, Wiernik PH, Wadler S. Interferon-induced acute renal failure: a case report and literature review. Med Oncol 1995;12:55-7.
16. Sudholt BA, Heironimus JD. Chronic myelogenous leukemia with nephrotic syndrome. Arch Intern Med 1983;143:168-9.
17. Gago ES, Luno E, Quinones L, Jonte F, Alvarez J. Chronic myelogenous leukemia and glomerulonephritis: report of a new case [letter]. Am J Med 1986;81:1121-2.
18. Madjan M, Dmoszynska A, Wojtaszko M, Spiewak H, Chibowski D, Siezieniewska Z, et al. Chronic myelogenous leukemia associated with rapidly progressive glomerulonephritis. Nephrol Dial Transplant 1994;9:562-3.
19. Carella AM, Pollicardo N, Raffo MR, Podesta M, Carlier P, Valbonesi M, et al. Intensive conventional chemotherapy can lead to a precocious overshoot of cytogenetically normal blood stem cells in chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia 1992;6:120-3.
20. Carella AM, Podesta M, Frassoni F, Raffo MR, Pollicardo N, Pungolino E, et al. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993;12:267-71.
21. Carella AM, Pollicardo N, Pungolino E, Raffo MR, Podesta M, Ferrero R, et al. Mobilization of cytogenetically 'normal' blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leuk Lymphoma 1993;9:477-83.
22. - cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia. J Hematother 1994;3:199-202.
23. Kantarjian H, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996;87:3069-81.
24. Glassock RJ. Therapy of idiopathic nephrotic syndrome in adults. Am J Nephrol 1993;13:422-8.
25. Fay J, Wolff S, Herzig R, Phillips G, Herzig G. Treatment of non-Hodgkin's lymphoma with intensive VP-16, cyclophosphamide, total body radiotherapy and autologous marrow transplantation [abstract 1006]. Proc Am Soc Clin Oncol 1990;9:260.
26. Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O'Brien S, Beran M, et al. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 1991;68:1201-7.
27. Kantarjian HM, Talpaz M, LeMaistre CF, Spinolo J, Spitzer G, Yau J, et al. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer 1991;67:2959-65.
28. Talpaz M, Kantarjian H, Hester J, Champlin R, Deisseroth A. Autologous "in vivo" purged bone marrow and peripheral stem cell transplant in chronic myelogenous leukemia (CML): induction of cytogenetic response and interferon-alpha (IFN-α) responsiveness [abstract]. Blood 1993; 82(Suppl 1):378a.
29. Reiffers J, Montastruc M, Cahn JY, Souillet G, Troncy J, Lebland V, et al. Autologous blood stem-cell transplantation and recombinant interferon alfa in chronic myeloid leukemia. Semin Hematol 1993;30(Suppl 3):51-2.
30. Barnett MJ, Eaves CJ, Phillips GL, Gascoyne RD, Hogge DE, Horsman DE, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994;84:724-32.
31. Carella AM, Cunningham I, Lerma E, Dejana A, Benvenuto E, Podesta M, et al. Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 1997;15:1575-82.
32. Southwest Pediatric Nephrology Study Group. Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. Kidney Int 1985;27:442-9.
33. Korbert SM, Schwartz MM, Lewis EJ. Primary focal segmentai glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994;23:773-83.
34. Anderson MS, Recant L. Fine structural alterations in the rat kidney following intraperitoneal bovine albumin. Am J Pathol 1962;40:555-69.
35. Vernier RL, Papermaster BW, Olness K, Binet E, Good RA. Morphologic studies of the mechanism of proteinuria. Am J Dis Child 1960;100:476-8.
36. Ashworth CT, James JA. Glomerular excretion of macromolecular substances. Electron microscopic study of rat kidney after administration of human serum albumin. Am J Pathol 1961;39:307-16.
37. Lannigan R, McQueen EG. The effect on the renal glomerular epithelial cells of proteinuria induced by infusions of human serum albumin in rabbits and rats. Br J Exp Pathol 1962;43:549-55.
38. Kurtz SM, Feldman JD. Morphologic studies of the normal and injured rat kidney following protein overload. Lab Invest 1962;11:167-76.
39. Fisher ER, Hellstrom HR. Mechanism of proteinuria: functional and ultrastructural correlation of effects of infusion of homologous and heterologous protein (bovine serum albumin) in the rat. Lab Invest 1962;11:617-37.
40. Marks MI, Drummond KN. Nephropathy and persistent proteinuria after albumin administration in the rat. Lab Invest 1970;23:416-20.
41. Bino T, Madar Z, Gertler A, Rosenberg H. The kidney is the main site of interferon degradation. J Interferon Res 1982;2:301-8.
42. Morel-Maroger L, Sloper IC, Vinter I, Biol MI, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in neonatal period. Lab Invest 1979;39:513-22.
43. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
44. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr., Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-6.
45. Niederau C, Heintges T, Lange S, Gulmann G, Niederman CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
46. Ponticelli C, Passerini P. Treatment of the nephrotic syndrome associated with primary glomerulonephritis. Kidney Int 1994;46:595-604.
47. Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am J Med 1987;82:938-44.
48. Medoza SA, Tune BM. Treatment of childhood nephrotic syndrome. J Am Soc Nephrol 1992;3:889-94.
49. Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid resistant focal segmental glomerulosclerosis. A reappraisal. Clin Nephrol 1984;21:109-13.
50. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84.
51. Meyrier A, Noel L-H, Auriche P, Callard P. Collaborative Group of the Société de Néphrologie, Broneer D. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994;45:1446-56.
52. Gansevoort RT, de Zeeuw D, de long PE. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993;22:202-6.
53. Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20:240-8.